Cargando…
Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years
Immune response induced by COVID-19 vaccine booster against delta and omicron variants was assessed in 65 adults (65–84 years old) early aftesr a first booster dose. An increase in SARS-CoV-2 neutralizing antibodies was shown in individuals not previously infected without evidence of an age-related...
Autores principales: | Durier, Christine, Ninove, Laetitia, Lefebvre, Maeva, Radenne, Anne, Desaint, Corinne, Ropers, Jacques, Bauer, Rebecca, Lebbah, Said, Carette, Diane, Lachatre, Marie, Lecompte, Anne-Sophie, Deplanque, Dominique, Botelho-Nevers, Elisabeth, Conrad, Anne, Dussol, Bertrand, Maakaroun-Vermesse, Zoha, Melica, Giovanna, Nicolas, Jean-François, Verdon, Renaud, Kiladjian, Jacques, Loubet, Paul, Schmidt-Mutter, Catherine, Dualé, Christian, Ansart, Séverine, Priet, Stéphane, Levier, Axel, Molino, Diana, Vieillard, Louis-Victorien, Parfait, Béatrice, Lelièvre, Jean-Daniel, Tartour, Eric, de Lamballerie, Xavier, Launay, Odile |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701678/ https://www.ncbi.nlm.nih.gov/pubmed/36437298 http://dx.doi.org/10.1038/s41598-022-24409-w |
Ejemplares similares
-
Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2022) -
Persistance à six mois des réponses immunitaires induites par une vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2 – cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2023) -
Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial
por: Janssen, Cécile, et al.
Publicado: (2022) -
Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022) -
1610P Humoral immune response to COVID-19 vaccination in patients with cancer: The ANRS0001S COV-POPART study
por: Luong Nguyen, L.B., et al.
Publicado: (2022)